Literature DB >> 26808063

UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance.

Ya-Xiao Chen1, Xiao-Jing Zhang2, Jia Huang1, Shu-Jun Zhou2, Fang Liu2, Lin-Lin Jiang1, Meiwan Chen2, Jian-Bo Wan3, Dong-Zi Yang4.   

Abstract

Polycystic ovary syndrome (PCOS), characterized with menstrual irregularities, hyperandrogenism and ovulatory abnormalities, is usually companied with insulin resistance (IR) and accounts for one of the most prevalent reproductive dysfunction of premenopausal women. Despite accumulating investigations, diagnostic standards of this pathological condition remain obscure. The aim of present study is to characterize the plasma metabolic characteristics of PCOS patients with and without IR, and subsequently identify the potential biomarkers for the diagnosis of PCOS and its IR complication. A total of 59 plasma samples from eligible healthy controls (CON, n=19), PCOS patients without IR (non-IR PCOS, n=19) and PCOS patients with IR (IR PCOS, n=21) were profiled by an ultra high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC/Q-TOFMS) followed by multivariate statistical analysis. Compared to the healthy controls, significant decrease in the levels of phosphocholines (PCs) and lyso PC (18:2), and increase in trilauric glyceride level were observed in the plasma of IR PCOS. Meanwhile, the significant increase in the levels of saturated fatty acids (palmitic acid and stearic acid) and decanoylcarnitine, and decrease in PC (36:2) and PS (36:0) were found in non-IR PCOS patients. Trilauric glyceride and decanoylcarnitine were identified as the potential biomarkers with the highest sensitivity and specificity for the diagnosis of PCOS patients with and without IR, respectively. Furthermore, based on these alterations of metabolites, MetPA network pathway analysis suggested a profound involvement of the abnormalities of glycerophospholipid, glycerolipid and fatty acid metabolisms in the pathogenesis of PCOS and IR complications. Collectively, LC-MS-based metabolomics provides a promising strategy for complementary diagnosis of PCOS and its IR complication and offers a new insight to understand their pathogenesis mechanisms.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Insulin resistance; Metabolomics; Polycystic ovary syndrome; UHPLC/Q-TOFMS

Mesh:

Substances:

Year:  2016        PMID: 26808063     DOI: 10.1016/j.jpba.2016.01.025

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  Untargeted metabolomic approach to study the serum metabolites in women with polycystic ovary syndrome.

Authors:  Ying Yu; Panli Tan; Zhenchao Zhuang; Zhejiong Wang; Linchao Zhu; Ruyi Qiu; Huaxi Xu
Journal:  BMC Med Genomics       Date:  2021-08-20       Impact factor: 3.063

Review 2.  Follicular Fluid: A Powerful Tool for the Understanding and Diagnosis of Polycystic Ovary Syndrome.

Authors:  Ana Teresa Brinca; Ana Cristina Ramalhinho; Ângela Sousa; António Hélio Oliani; Luiza Breitenfeld; Luís A Passarinha; Eugenia Gallardo
Journal:  Biomedicines       Date:  2022-05-27

3.  Concurrent profiling of polar metabolites and lipids in human plasma using HILIC-FTMS.

Authors:  Xiaoming Cai; Ruibin Li
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

4.  Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome.

Authors:  Mariona Jové; Irene Pradas; Alba Naudí; Susana Rovira-Llopis; Celia Bañuls; Milagros Rocha; Manuel Portero-Otin; Antonio Hernández-Mijares; Victor M Victor; Reinald Pamplona
Journal:  Oncotarget       Date:  2017-12-17

5.  UPLC/Q‑TOF‑MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome.

Authors:  Xuemei Fan; Jianfa Jiang; Zhiqiang Huang; Jumei Gong; Yiming Wang; Wei Xue; Yan Deng; Yanfang Wang; Tingping Zheng; Aijun Sun; Guoan Luo
Journal:  Mol Med Rep       Date:  2018-11-12       Impact factor: 2.952

6.  Effects of L-carnitine supplementation for women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Mohd Falihin Mohd Shukri; Mohd Noor Norhayati; Salziyan Badrin; Azidah Abdul Kadir
Journal:  PeerJ       Date:  2022-09-16       Impact factor: 3.061

7.  Follicular metabolic changes and effects on oocyte quality in polycystic ovary syndrome patients.

Authors:  Yan Zhang; Lingyan Liu; Tai-Lang Yin; Jing Yang; Cheng-Liang Xiong
Journal:  Oncotarget       Date:  2017-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.